Literature DB >> 26202857

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study.

Peter M Voorhees1, Robert Z Orlowski2, Flora Mulkey3, Peter Watson4, Susan Geyer5, Ben L Sanford3, Elizabeth Bennett3, Asher A Chanan-Khan6, Clara D Bloomfield7, Richard A Larson8.   

Abstract

Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the near-complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence of treatment-related ≥Grade 3 non-haematological toxicity (80% vs. 51%, P = 0·020). Median overall survival was 5·6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  anthracyclines; international staging system; multiple myeloma; proteasome inhibitors

Mesh：

Substances：

Year:  2015        PMID： 26202857      PMCID： PMC5569902          DOI： 10.1111/bjh.13592

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  10 in total

1.  Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Authors:  Robert Z Orlowski; Arnon Nagler; Pieter Sonneveld; Joan Bladé; Roman Hajek; Andrew Spencer; Jesús San Miguel; Tadeusz Robak; Anna Dmoszynska; Noemi Horvath; Ivan Spicka; Heather J Sutherland; Alexander N Suvorov; Sen H Zhuang; Trilok Parekh; Liang Xiu; Zhilong Yuan; Wayne Rackoff; Jean-Luc Harousseau
Journal:  J Clin Oncol       Date:  2007-08-06       Impact factor: 44.544

2.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Authors:  S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

3.  Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

Authors:  Robert Z Orlowski; Peter M Voorhees; Reynaldo A Garcia; Melissa D Hall; Fred J Kudrik; Tammy Allred; Anandhi R Johri; Paul E Jones; Anastasia Ivanova; Hendrik W Van Deventer; Don A Gabriel; Thomas C Shea; Beverly S Mitchell; Julian Adams; Dixie-Lee Esseltine; Elizabeth G Trehu; Marie Green; Mary Jo Lehman; Susan Natoli; Jason M Collins; Celeste M Lindley; E Claire Dees
Journal:  Blood       Date:  2004-12-30       Impact factor: 22.113

4.  Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.

Authors:  H Avet-Loiseau; B G M Durie; M Cavo; M Attal; N Gutierrez; J Haessler; H Goldschmidt; R Hajek; J H Lee; O Sezer; B Barlogie; J Crowley; R Fonseca; N Testoni; F Ross; S V Rajkumar; P Sonneveld; J Lahuerta; P Moreau; G Morgan
Journal:  Leukemia       Date:  2012-10-03       Impact factor: 11.528

5.  Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).

Authors:  E Kastritis; K Zervas; A Symeonidis; E Terpos; S Delimbassi; N Anagnostopoulos; E Michali; A Zomas; E Katodritou; D Gika; A Pouli; D Christoulas; M Roussou; Z Kartasis; T Economopoulos; M A Dimopoulos
Journal:  Leukemia       Date:  2009-02-19       Impact factor: 11.528

6.  Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.

Authors:  Andrzej J Jakubowiak; Tara Kendall; Ammar Al-Zoubi; Yasser Khaled; Shin Mineishi; Asra Ahmed; Erica Campagnaro; Christine Brozo; Thomas Braun; Moshe Talpaz; Mark S Kaminski
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

7.  Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Authors:  J Bladé; D Samson; D Reece; J Apperley; B Björkstrand; G Gahrton; M Gertz; S Giralt; S Jagannath; D Vesole
Journal:  Br J Haematol       Date:  1998-09       Impact factor: 6.998

8.  Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.

Authors:  G Srivastava; V Rana; M Q Lacy; F K Buadi; S R Hayman; A Dispenzieri; M A Gertz; D Dingli; S Zeldenrust; S Russell; A McCurdy; P Kapoor; R Kyle; S V Rajkumar; S Kumar
Journal:  Leukemia       Date:  2013-05-07       Impact factor: 11.528

9.  Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.

Authors:  Paul G Richardson; Wanling Xie; Constantine Mitsiades; Asher A Chanan-Khan; Sagar Lonial; Hani Hassoun; David E Avigan; Anne Louise Oaklander; David J Kuter; Patrick Y Wen; Santosh Kesari; Hannah R Briemberg; Robert L Schlossman; Nikhil C Munshi; L Thompson Heffner; Deborah Doss; Dixie-Lee Esseltine; Edie Weller; Kenneth C Anderson; Anthony A Amato
Journal:  J Clin Oncol       Date:  2009-06-15       Impact factor: 44.544

10.  Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.

Authors:  Ingemar Turesson; Ramon Velez; Sigurdur Y Kristinsson; Ola Landgren
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544
  10 in total
  6 in total

Review 1.  Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma.

Authors:  Pilar de la Puente; Abdel Kareem Azab
Journal:  Eur J Haematol       Date:  2017-03-28       Impact factor: 2.997

2.  Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.

Authors:  Robert Z Orlowski; Arnon Nagler; Pieter Sonneveld; Joan Bladé; Roman Hajek; Andrew Spencer; Tadeusz Robak; Anna Dmoszynska; Noemi Horvath; Ivan Spicka; Heather J Sutherland; Alexander N Suvorov; Liang Xiu; Andrew Cakana; Trilok Parekh; Jesús F San-Miguel
Journal:  Cancer       Date:  2016-05-18       Impact factor: 6.860

3.  Shikonin promotes adriamycin‑induced apoptosis by upregulating caspase‑3 and caspase‑8 in osteosarcoma.

Authors:  Qing Yang; Suoyuan Li; Zeze Fu; Binhui Lin; Zifei Zhou; Zhuoying Wang; Yingqi Hua; Zhengdong Cai
Journal:  Mol Med Rep       Date:  2017-06-08       Impact factor: 2.952

Review 4.  Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma.

Authors:  Claire Gourzones; Caroline Bret; Jerome Moreaux
Journal:  Front Genet       Date:  2019-09-18       Impact factor: 4.599

5.  Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety.

Authors:  Yujia Zhai; Dai Yuan; Xueling Ge; Shunfeng Hu; Peipei Li; Xiaosheng Fang; Ying Li; Xiangxiang Zhou; Xin Wang
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244

Review 6.  Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy.

Authors:  Ewelina Piktel; Katarzyna Niemirowicz; Marzena Wątek; Tomasz Wollny; Piotr Deptuła; Robert Bucki
Journal:  J Nanobiotechnology       Date:  2016-05-26       Impact factor: 10.435
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.